Strategic Use of New Generation Antidepressants for Depression

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to establish the optimum treatment strategy for first-line and second-line antidepressants in the acute phase treatment of major depression.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyoto University
• Collaborator: National Center of Neurology and Psychiatry, Japan
• Treatments: Antidepressive Agents; Mianserin; Mirtazapine; Sertraline

Criteria

Inclusion Criteria:

• non-psychotic unipolar major depressive episode (Diagnostic and Statistical Manual, Fourth Edition [DSM-IV]) in the preceding month

• age 25-75

• starting treatment with sertraline clinically indicated

• tolerability to sertraline 25 mg/d ascertained

• can understand and sign informed consent form

• can be contacted by telephone for symptom severity and adverse events

Exclusion Criteria:

• have received antidepressants, mood stabilizers, antipsychotics, psychostimulants, electroconvulsive therapy (ECT) or depression-specific psychotherapies in the preceding month

• history of schizophrenia, schizoaffective disorder or bipolar disorder

• current dementia, borderline personality disorder, eating disorder or substance dependence

• physical disease interfering with sertraline or mirtazapine treatment

• allergy to sertraline or mirtazapine

• terminal physical illness

• currently pregnant or breast-feeding

• high risk of imminent suicide

• requiring compulsory admission

• expected to change doctors within 6 months

• cohabiting relatives of research staff

• cannot understand Japanese